Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI Test in GP Patients
NCT00318084Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Primary endpoint: Diagnostic test characteristics (PPV, NPV) at 2 weeks. Started Jan 2003; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00318084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318084.